Results 101 to 110 of about 2,340,035 (348)

Study of immunomodulatory activity of aqueous extract of Carica papaya in Wistar rats

National Journal of Physiology, Pharmacy and Pharmacology, 2016
Background: Various parts of Carica papaya (CP) Linn. have been traditionally used as ethnomedicine for a number of disorders including cancer. There have been anecdotes of patients with advanced cancers achieving remission following consumption of tea ...
K. S. Ramesh, Ravindranath S. Kambimath, N. Venkatesan   +2 more
doaj   +1 more source

Hypersensitivity pneumonitis: a complex lung disease

Clinical and Molecular Allergy, 2017
Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, is a respiratory syndrome involving the lung parenchyma and specifically the alveoli, terminal bronchioli, and alveolar interstitium, due to a delayed allergic reaction.
G. R. Riario Sforza, A. Marinou
semanticscholar   +1 more source

Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata [PDF]

, 2020
Erythema nodosum (EN) is a form of septal panniculitis, which is believed to represent a delayed hypersensitivity reaction activated by infectious agents, drugs, granulomatous and autoimmune diseases, pregnancy, and malignancies.
Badavanis, George, Kapranos, Nikiforos, Monastirli, Alexandra, Pasmatzi, Efstathia, Tsambaos, Dionysios   +4 more
core  

Therapeutic Drug Monitoring and Methods of Quantitation for Carbamazepine [PDF]

, 2017
Carbamazepine is an early anticonvulsant still used today in the treatment of several forms of epilepsy. An active metabolite in the human body contributes to its pharmacological effect.
Ana Vlasceanu, Cristian Balalau, Cristian Tuchila, Cristina Pirvu, Daniela Baconi, Denisa Balalau, Miriana Stan, null null   +7 more
core   +4 more sources

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Modification of established rejection of canine kidney and liver homografts with antilymphocyte gamma-G globulin [PDF]

, 1969
Heterologous ALG was administered to ten canine recipients of renal homografts and one recipient of an orthotopic liver. Treatment was started after rejection was well established.
Kashiwagi, N, Kolff, J, Putnam, CW, Smith, GV, Starzl, TE   +4 more
core  

Allergic bronchopulmonary aspergillosis: diagnostic and treatment challenges [PDF]

, 2016
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, occurring mostly in asthmatic and cystic fibrosis patients, caused by an abnormal T-helper 2 lymphocyte response of the host to Aspergillus fumigatus antigens.
CINICOLA, BIANCA LAURA, DUSE, MARZIA, Laitano, Rossella, LEONARDI, LUCIA   +3 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor

Frontiers in Pharmacology
Background: Cystic fibrosis transmembrane conductance regulator modulators are the only available treatment for cystic fibrosis. Although elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is well-tolerated, rash has been reported as very frequent. In severe
L. Gómez-Ganda, P. Galván-Blasco, P. Galván-Blasco, A. Fernández-Polo, V. Cardona, V. Cardona, B. García-Palop, CJ Parramón-Teixidó, E. Polverino, A. Álvarez-Fernández   +9 more
doaj   +1 more source

The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats. [PDF]

, 2013
Corticotropin releasing factor receptor 1 (CRF1) is the key receptor that mediates stress-related body responses. However to date there are no CRF1 antagonists that have shown clinical efficacy in stress-related diseases.
Czimmer, József, Hoffman, Diane C, Kehne, John, Luckey, Andrew, Maynard, George D, Million, Mulugeta, Taché, Yvette, Zhao, Jing-Fang   +7 more
core   +2 more sources